Kimon Argyropoulos earned his MD from the National and Kapodistrian University of Athens, Greece, in 2011. His research focuses on the immunobiology of indolent lymphoid neoplasms, with an emphasis on aberrant lymphocyte signaling as a potent driver of human lymphomagenesis. He is a recipient of the SASS Foundation post-doctoral fellowship award for his studies on BCR signaling in Waldesntröm’s Macroglobulinemia.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Kimon Argyropoulos discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.